Kalaris Therapeutics (KLRS) Misses Q2 EPS by 61c
Tweet
Share
E-mailGet Alerts KLRS Hot Sheet
Join SI Premium – FREE
Kalaris Therapeutics (NASDAQ: KLRS) reported Q2 EPS of ($0.61).
For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Cineverse (CNVS) PT Raised to $14 at Benchmark on Revenue, Earnings Beat
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
